Lv42
796 积分 2024-07-10 加入
Health policy and public health implications of obesity in China
35分钟前
已完结
Epidemiology and determinants of obesity in China
47分钟前
已完结
Acarbose in the treatment of elderly patients with type 2 diabetes
4天前
已完结
乳腺癌PAM通路抑制剂不良反应管理专家共识（2026版）
4天前
已完结
Glucose Control, Sulfonylureas, and Insulin Treatment in Elderly People With Type 2 Diabetes and Risk of Severe Hypoglycemia and Death: An Observational Study
6天前
已完结
Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (ATTAIN-2): a phase 3, double-blind, randomised, multicentre, placebo-controlled trial
6天前
已完结
Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (ATTAIN-2): a phase 3, double-blind, randomised, multicentre, placebo-controlled trial
6天前
已完结
Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment
6天前
已完结
Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment
6天前
已完结
皖公网安备34019202002308
